Chen Schor Buys 55,000 Shares of ACET
ACET's CEO makes a significant stock purchase amid positive analyst ratings.
Key Points
- Chen Schor, President & CEO of ACET, bought 55,000 shares on June 19, 2026.
- Shares of ACET traded near $8.35 on Wednesday, with various insiders also making purchases.
- Analysts from Jefferies and HC Wainwright maintain 'buy' ratings with targets up to $27.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Chen Schor, the President and CEO of ACET, recently bought 55,000 shares of the company on June 19, 2026. This insider transaction was not part of a pre-arranged trading plan, indicating a personal decision to invest in the company.
Other Institutional Activity in ACET
RA Capital Management, L.P. increased its stake in ACET by 234,375 shares, bringing its total to 1,182,624 shares valued at about $8.05 million, a 24.7% increase. Meanwhile, Citadel Advisors LLC boosted its holdings by 274,009 shares to 381,823 shares, marking a significant 254.1% increase, with a total value of approximately $2.6 million. Vanguard Capital Management LLC opened a new position with 336,524 shares worth around $2.29 million. On the other hand, Woodline Partners LP reduced its holdings by 311,876 shares, ending with 313,124 shares valued at $2.13 million, a decrease of 49.9%.
Adicet Bio, Inc. Stock Down 8.4%
Shares of ACET traded near $8.35 on Wednesday. The stock has seen varied activity from institutional investors, indicating differing views on its potential. While some funds are increasing their stakes, others are reducing or opening new positions.
$ACET stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Adicet Bio, Inc.
In addition to Chen Schor's purchase, several other insiders acquired shares on June 21, 2026. Lloyd Klickstein, Jeffrey Chodakewitz, Steve Dubin, Andrew Sinclair, Michael Grissinger, and Katie Peng each bought 4,200 shares. These transactions were also not part of any pre-arranged trading plans, suggesting a shared confidence in the company's prospects among its leadership.
Analysts Set New Price Targets
On May 5, 2026, Jefferies assumed coverage of ACET with a 'buy' rating and set a price target of $19. HC Wainwright & Co. maintained its 'buy' rating with a target of $27 as of March 23, 2026. These positive ratings reflect a strong analyst consensus on the stock's potential, with targets suggesting significant upside from current levels.
Bottom Line
Chen Schor's recent purchase of ACET shares, along with other insider buys, signals a positive outlook from the company's leadership. Institutional activity shows a mix of increased stakes and new positions, reflecting varied investor sentiment. Analyst ratings remain optimistic, with multiple 'buy' recommendations and high price targets, suggesting potential growth for the stock. As always, it's important to remember that insider and institutional trades are backward-looking indicators and may not reflect current positions.
Get Adicet Bio, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ACET, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.